Influence of Tightly Glucose Control on Hyperglycemic Toxicity and Protein Catabolism in Critically Ill Patients

This study has been completed.
Sponsor:
Information provided by:
Kaohsiung Veterans General Hospital.
ClinicalTrials.gov Identifier:
NCT01227148
First received: October 15, 2010
Last updated: October 22, 2010
Last verified: April 2006
  Purpose

To compare the differences of urinary nitrogen excretion, nitrogen balance and clinical outcomes between tightly insulin therapy and conventional insulin therapy in the ICU.


Condition Intervention Phase
Critically Ill Patients
Other: Tightly glucose control
Other: Conventional glucose control
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Influence of Tightly Glucose Control on Hyperglycemic Toxicity and Protein

Resource links provided by NLM:


Further study details as provided by Kaohsiung Veterans General Hospital.:

Primary Outcome Measures:
  • 24-hour urinary urea nitrogen(UUN)excretion, nitrogen balance and serum albumin and prealbumin. [ Time Frame: up to the 14th study day ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • ICU day, ventilator day, hospital day, episodes of acute renal injury, bacteremia, blood transfusion, gastrointestinal (GI) bleeding, hypoglycemia, and hospital mortality rate. [ Time Frame: up to ICU discharge ] [ Designated as safety issue: Yes ]

Enrollment: 112
Study Start Date: April 2006
Study Completion Date: December 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tightly glucose conntrol Other: Tightly glucose control
A continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method
Other Name: euglycemic control
Active Comparator: Conventional glucose control Other: Conventional glucose control
a continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.
Other Name: conventional insulin therapy

Detailed Description:

Critical illness is associated with increased circulating concentrations of proinflammatory cytokines, such as tumor necrosis factor (TNF-α), interleukin (IL)-1, and IL-6 which may be important mediators of insulin resistance and results in hyperglycemia. Altered glucose metabolism was caused by release of counter regulatory hormones such as glucagons; epinephrine and cortisol oppose the normal action of insulin, leading to an increase in skeletal muscle proteolysis. It did not know whether tightly glucose control had beneficial effect in urinary nitrogen excretion and nitrogen balance.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients admitted to the adult ICU who had baseline blood glucose > 180 mg/dl
  • expected to require treatment in the ICU on 3 or more consecutive days.

Exclusion Criteria:

  • pregnant patients
  • patients with chronic renal loss (Chronic renal loss was defined as persistent acute renal failure, complete loss of kidney function > 4 weeks)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01227148

Locations
Taiwan
Kaohsiung Veterans General Hospital
Kaohsiung, Taiwan, 813
Sponsors and Collaborators
Kaohsiung Veterans General Hospital.
Investigators
Principal Investigator: Chien-Wei Hsu, MD Kaohsiung Veterans General Hospital.
  More Information

No publications provided by Kaohsiung Veterans General Hospital.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Chien-Wei Hsu, Kaohsiung Veterans General Hospital
ClinicalTrials.gov Identifier: NCT01227148     History of Changes
Other Study ID Numbers: VGHKS95-070
Study First Received: October 15, 2010
Last Updated: October 22, 2010
Health Authority: Taiwan: Department of Health

Keywords provided by Kaohsiung Veterans General Hospital.:
critical care, glycemic control, insulin, nitrogen balance

Additional relevant MeSH terms:
Critical Illness
Disease Attributes
Pathologic Processes
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 20, 2014